Abstract
PROteolysis-TArgeting Chimeras (PROTACs) have emerged as an innovative drug development platform. However, most PROTACs have been generated empirically because many determinants of PROTAC specificity and activity remain elusive. Through computational modelling of the entire NEDD8-VHL Cullin RING E3 ubiquitin ligase (CRL<sup>VHL</sup>)/PROTAC/BCL-xL/UbcH5B(E2)-Ub/RBX1 complex, we find that this complex can only ubiquitinate the lysines in a defined band region on BCL-xL. Using this approach to guide our development of a series of ABT263-derived and VHL-recruiting PROTACs, we generate a potent BCL-xL and BCL-2 (BCL-xL/2) dual degrader with significantly improved antitumor activity against BCL-xL/2-dependent leukemia cells. Our results provide experimental evidence that the accessibility of lysines on a target protein plays an important role in determining the selectivity and potency of a PROTAC in inducing protein degradation, which may serve as a conceptual framework to guide the future development of PROTACs.
Introduction: The Challenge of PROTAC Specificity
Proteolysis-Targeting Chimeras (PROTACs) represent a revolutionary class of therapeutics that hijack the cell's natural disposal system—the Ubiquitin-Proteasome System—to selectively destroy disease-causing proteins. Unlike traditional inhibitors, PROTACs do not need to maintain high occupancy of a binding site; they act catalytically to tag targets for degradation. However, designing effective PROTACs remains a significant challenge, often relying on empirical "trial-and-error" methods.
A prominent example of this challenge is found in the BCL-2 family of proteins, which are critical regulators of apoptosis (programmed cell death) and are frequently overexpressed in cancers. Previous efforts produced DT2216, a PROTAC that successfully degrades BCL-xL but fails to degrade its close relative BCL-2, despite binding both proteins with high affinity. This study sought to understand the geometric and structural rules governing this selectivity to develop a more effective dual-target degrader.
Methods: Structural Modeling and Validation
To move beyond empirical design, the researchers combined computational structural biology with experimental validation. They utilized structures from the Protein Data Bank (PDB), including the Cullin-RING E3 ligase components (3DQV/5N4W) and BCL-xL/BCL-2 bound to inhibitors (4QNQ/4LVT).
The team built a complete model of the massive E3 ligase complex (CRL<sup>VHL</sup>) bound to the PROTAC and the target protein. They employed Normal Mode Analysis (NMA) to simulate the natural flexibility of the E3 ligase machinery, identifying which regions of the target protein the ubiquitin-tagging arm (the E2 enzyme) could physically reach. These models were then validated using site-directed mutagenesis in HEK293T and HeLa cells, creating "lysine-only" mutants of BCL-xL to pinpoint which surface residues were essential for degradation.
Key Insights: The "Ubiquitination-Accessible Band"
The study's central finding is the "Accessible Band" Theory. The researchers discovered that proximity alone is insufficient for degradation; ubiquitination can only occur if a surface lysine on the target protein falls within a specific "band" defined by the reach and swing of the E3 ligase complex. If a protein's lysines are positioned outside this band or are shielded by other residues, the protein remains undegradable by that specific PROTAC/E3 pair.
This geometric constraint explained why previous degraders like DT2216 failed to hit BCL-2: the lysines on BCL-2 were geometrically unreachable in the ternary complex. By shifting the PROTAC's linker attachment point on the ABT263 warhead, the authors were able to rotate the target protein relative to the E3 ligase, bringing BCL-2's lysines into the "strike zone."
Results: Potency and Safety of 753b
This structure-guided approach led to the development of 753b, a potent dual degrader of BCL-xL and BCL-2. The lead compound achieved a DC<sub>50</sub> (concentration for 50% degradation) of 6 nM for BCL-xL and 48 nM for BCL-2. In Kasumi-1 leukemia cells, 753b demonstrated nearly 20 times the potency of the BCL-xL-selective DT2216.
Crucially, 753b maintains a favorable safety profile regarding platelets. While BCL-xL inhibitors often cause thrombocytopenia (platelet destruction), 753b spares platelets because they express very low levels of VHL, the E3 ligase recruited by the PROTAC. Mechanistic studies confirmed that 753b's activity is strictly dependent on VHL and the proteasome pathway.
Discussion and Future Directions
While the "accessible band" model provides a powerful framework for PROTAC design, it is currently specific to the VHL E3 ligase. Future work will need to adapt this model for other ligases, such as Cereblon (CRBN), which possess different geometries and flexibilities. Additionally, while computational models are highly predictive, high-resolution cryo-EM structures of the full ternary complexes will be essential for further refining these geometric rules. Nevertheless, this study establishes a conceptual shift from empirical to structure-guided PROTAC development, offering a path toward more potent and selective cancer therapeutics.
Summary updated